Compare Merck & Co., Inc. (MRK) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Otis Worldwide Corp — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Otis Worldwide Corp trades at $72.22 (market cap $28.20B). The key difference: Merck & Co., Inc. is far larger — about 10.9× Otis Worldwide Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | OTIS | |
|---|---|---|
Market Cap | $307.25B | $28.20B |
Sector | Health | Industrials |
52-Week High | $129.52 | $100.99 |
52-Week Low | $77.60 | $69.34 |
Enterprise Value | $350.66B | $35.58B |
Dividend Yield | 2.73% | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Otis Worldwide (OTIS) trades at $71.95, down 2.04% recently, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed Q1 2026 earnings, missing EPS estimates but showing strong service growth. Revenue trends are stable, with 2025 revenue at $14.43B and net income of $1.38B. Analyst consensus is a Buy with a $91.00 price target, implying significant upside. Recent news highlights modernization initiatives and Q2 earnings focus.
The outlook for OTIS is cautiously optimistic, with potential driven by service segment strength and strategic upgrades, but risks include margin pressures from tariffs and economic headwinds. Valuation at a P/E of 19.54 is reasonable, yet debt levels and recent earnings misses warrant monitoring. Institutional sentiment is mixed, with 38% Buy ratings offset by high debt-to-asset ratio of 75.54% as of 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
